Get the Stockscreener App
1.31
0.77%
0.01
After Hours:
1.31
iBio Inc stock is traded at $1.31, with a volume of 265.03K.
It is up +0.77% in the last 24 hours and down -10.27% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$1.30
Open:
$1.29
24h Volume:
265.03K
Relative Volume:
0.32
Market Cap:
$65.08M
Revenue:
$300.00K
Net Income/Loss:
$-27.61M
P/E Ratio:
-2.2676
EPS:
-0.5777
Net Cash Flow:
$-22.17M
1W Performance:
-3.68%
1M Performance:
-10.27%
6M Performance:
-53.71%
1Y Performance:
+61.47%
1-Day Range:
$1.28
$1.33
1-Week Range:
$1.2101
$1.37
52-Week Range:
$0.7708
$3.82
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.31 | 73.03M | 300.00K | -27.61M | -22.17M | -0.5777 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-26 | Initiated | Raymond James | Outperform |
| Jun-05-26 | Initiated | B. Riley Securities | Buy |
| Oct-21-25 | Initiated | Oppenheimer | Outperform |
| Oct-17-25 | Initiated | Leerink Partners | Outperform |
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
View All
iBio Inc Stock (IBIO) Latest News
iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Ibio Stock Price Forecast. Should You Buy IBIO? - StockInvest.us
iBio, Inc. SEC Filing (Sep 4, 2026) - Stock Titan
Hundreds of millions of new shares on ballot at iBio (IBIO) - Stock Titan
iBio, Inc. Common Stock (NASDAQ: IBIO) Share Price, IBIO Stock News, IBIO Share Price & Updates - Kalkine
iBio, Inc. (NASDAQ:IBIO) Receives Average Rating of "Buy" from Brokerages - MarketBeat
iBio Q2 EPS Forecast Decreased by Brookline Capital Markets - MarketBeat
iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference - Yahoo Finance
Insiders Give Up US$33k As iBio Stock Drops To US$1.27 - simplywall.st
iBio Inc. (IBIO) Slides 6.6% to $1.27 as Biotech Stock Approaches Key SupportWyckoff Distribution - dars.gov.et
B. Riley Securities Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $6 - Moomoo
iBio Advances IBIO-600 Through First Phase 1 Dose Escalation As Cash And Investments Reach $88 Million - Pulse 2.0
iBio, Inc. Revenue Breakdown – NASDAQ:IBIO - TradingView
iBio FY2026 Net Loss Widens to $33M on Higher R&D Spending - Minichart
iBio FY 2026: Revenue $100K, Net income ($33.04M), EPS ($0.32) — 10-K Summary - TradingView
iBio reports $33 million loss for fiscal 2026, advances pipeline By Investing.com - Investing.com Canada
IBio Reports $33.0 Million Fiscal 2026 Net Loss as Phase 1 Advances - Moomoo
iBio Reports $33.0 Million Fiscal 2026 Net Loss as Phase 1 Advances - Quiver Quantitative
IBIO: Advanced clinical pipeline and secured funding, extending cash runway into fiscal 2028 - TradingView
iBio (NASDAQ:IBIO) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
iBio reports FY2026 net loss of $33.0M, revenue $0.1M and $88.0M cash and investments - TradingView
iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - The Manila Times
iBio Reports Fiscal 2026 Financial Results and Corporate Update Highlighting Clinical and Pipeline Progress - Quiver Quantitative
IBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - marketscreener.com
iBio FY26 Results: Net loss widens 80% to $33.0M, R&D up 136% - scanx.trade
iBio (IBIO) Expected to Release Quarterly Earnings on Friday - MarketBeat
iBio (NYSE: IBIO) seeks 500M shares, revises equity plan for warrants - Stock Titan
iBio (IBIO) Chart: Closes 1.72% Lower at $1.43 for the Current Session; Current Setup: the Near-Term Reference Band Stretches From $1.36 to $1.50 in the Available RecordMax Pain Level - vinanet.vn
iBio Inc. (IBIO) Edges Higher Amid Biotech Sector Volatility: Key Levels to WatchAAII Neutral - vinanet.vn
Molly Carr Net Worth (2026) - GuruFocus
iBio (NASDAQ:IBIO) Rating Increased to Hold at Wall Street Zen - MarketBeat
Lynx1 Capital Management (IBIO) corrects 5.4% iBio stake including 2.8M warrant shares - Stock Titan
Vestal Point Capital (IBIO) discloses 4.0M-share iBio position including warrants - Stock Titan
Cormorant Asset Management (IBIO) discloses 9.99% iBio stake via stock and warrants - Stock Titan
Affinity Asset Advisors (IBIO) discloses 5.07M-share, 9.99% stake in iBio - Stock Titan
iBio Inc. (IBIO) Jumps 6.79% to $1.5 as Stock Tests Key Resistance at $1.58Growth Factor - dars.gov.et
IBIO Q2 2026 Earnings: Narrower Loss and 5% Stock Pop Amid Pipeline ProgressGuidance Revision Trend - vinanet.vn
iBio Inc (IBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
iBio, Inc. (NASDAQ:IBIO) Given Average Rating of "Buy" by Analysts - MarketBeat
iBio Inc (IBIO) Stock News Today - TradingKey
NAGE Stock Price and Chart — NASDAQ:NAGE - TradingView
iBio Appoints Molly Carr as Chief Medical Officer - The Globe and Mail
iBio Expands Must-have Cardiometabolic and Obesity Pipeline Investor through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio - Diario AS
IBIO 8-K & SEC Filings - Yahoo Finance
iBio Inc. (IBIO) Edges Higher by 2.82% as Shares Test Key Resistance ZoneATR Trailing Stop - dars.gov.et
iBio (IBIO) awards 430,000 stock options to its Chief Medical Officer - Stock Titan
iBio appoints Molly Carr as chief medical officer By Investing.com - Investing.com India
iBio appoints Molly Carr as chief medical officer - Investing.com
Molly Carr named Chief Medical Officer at iBio - TradingView
iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer - Yahoo Finance
iBio Appoints Endocrinologist Molly Carr as Chief Medical Officer to Advance Obesity and Cardiometabolic Drug Pipeline – Minichart - Minichart
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):